January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
43 citations
,
May 1978 in “JAMA” Minoxidil controls blood pressure but may cause kidney damage and needs diuretics to prevent swelling.
11 citations
,
March 2020 in “American Journal of Medical Genetics Part A” A mutation in the EDNRA gene causes Oro-Oto-Cardiac syndrome, affecting face and heart development.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
3 citations
,
June 2022 in “e-Journal of Cardiovascular Medicine” Ischemia-modified albumin is not effective for diagnosing stable angina compared to exercise stress tests.
May 2025 in “Journal of Nanobiotechnology” The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
July 2026 in “Journal of the American Academy of Dermatology”
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
2 citations
,
August 2019 in “PubMed” A specific enzyme that activates the hair growth medication minoxidil when applied to the skin was identified.
52 citations
,
April 2002 in “Brain Research” Lower allopregnanolone levels increase stress-related dopamine release in the brain.
12 citations
,
May 2019 in “Molecular Medicine Reports” Forsythiaside A helps reduce brain damage from lack of blood flow by activating certain protective pathways.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
5 citations
,
January 2015 in “Journal of clinical & experimental dermatology research” MorrF improves hair growth better than minoxidil alone.
2 citations
,
August 2024 in “JAAD International” Combining low-dose oral minoxidil and spironolactone may improve hair growth safely.
181 citations
,
July 2004 in “Journal of controlled release” Smaller nanoparticles improve minoxidil absorption through hair follicles.
May 2019 in “The Journal of Sexual Medicine” Drinking alcohol before taking flibanserin does not increase the risk of severe low blood pressure or fainting.
46 citations
,
March 2009 in “Die Pharmazie” Minoxidil-loaded nanostructured lipid carriers are effective for topical use.
November 2025 in “Clinical and Translational Allergy” The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
1 citations
,
December 2022 in “Biomolecules & therapeutics” Minoxidil may help reduce aging effects in brain cells.
4 citations
,
January 2014 in “RSC Advances” A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
14 citations
,
January 2020 in “International Journal of Biological Sciences” Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.
Potassium channel openers like minoxidil boost hair growth.
Baicalin may effectively treat hair loss by inhibiting 5α-reductase.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
October 2023 in “Journal of The American Academy of Dermatology” Taking a small dose of the hair growth medicine minoxidil by mouth does not really change your blood pressure.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
19 citations
,
September 2020 in “Pharmaceutics” Sodium Valproate nanospanlastics could be a safe and effective treatment for Androgenic Alopecia, with fewer side effects than minoxidil.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.